Renedil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Renedil

Quick Facts

Property Description
Active ingredient Felodipine
Form Extended-Release (Prolonged-Release) Tablet
Pharmacological Class Antihypertensive Drug, Dihydropyridine Calcium Channel Blocker
General Purpose Reduction of systemic blood pressure
Origin Synthetic

What Type of Drug is Renedil?

Renedil is a synthetic, prescription-only medicine containing the single active substance, Felodipine, which places it within the major pharmacological group of antihypertensive drugs. Specifically, it is defined as a dihydropyridine calcium channel blocker or calcium antagonist. The drug's classification, which is clinically recognized for its high vascular selectivity, means it primarily targets the smooth muscles in blood vessel walls rather than directly affecting the heart's rhythm. Renedil is supplied as a single-ingredient product (monotherapy), typically positioned for adult patients requiring sustained vascular control.

Understanding Renedil's Composition and Extended-Release Form

Renedil is manufactured as an oral dosage form, specifically an extended-release tablet formulated for controlled delivery of Felodipine. This specialized formulation is a key differentiator, as it utilizes a specialized matrix to prevent rapid absorption. The system is designed to release the active substance gradually and consistently into the bloodstream over a prolonged period. This sustained-release action is crucial for maintaining a steady therapeutic effect throughout the day, which supports its use in managing chronic conditions. This controlled-release profile ensures a consistent, non-fluctuating reduction in peripheral vascular resistance.

What is the General Purpose of Renedil’s Action?

The general purpose of Renedil is to control and stabilize systemic blood pressure by facilitating peripheral vasodilation, which is the widening of the body's arterial pathways. Renedil achieves this by acting as a calcium channel inhibitor within the smooth muscle of the blood vessel walls, which prevents vessel contraction. By reducing the overall force against which the heart must pump, Renedil lessens the strain on the cardiovascular system. This mechanism is generally utilized in scenarios requiring long-term maintenance of stable blood pressure.

Regulatory References

  1. Felodipine: MedlinePlus Drug Information

What side effects are possible with Renedil?

Possible Side Effects and Safety Information

The official safety profile for Renedil (Felodipine) is defined by classifying adverse reactions based on their frequency and the body system affected, according to government regulatory standards.

Frequency-Classified Adverse Reactions

The most frequently documented side effect is Peripheral Edema (swelling, often of the ankles), which is classified as Very Common (affecting more than 1 in 10 patients). Common reactions (affecting between 1 in 10 and 1 in 100 patients) often include headache, flushing, and dizziness. These common effects are generally related to the medicine's vasodilatory action and are noted to be transient, often appearing at the start of treatment or following a dose increase.

System-Organ-Class Safety and Constraints

Adverse reactions are grouped by System-Organ Class, with effects reported in the Vascular Disorders (e.g., flushing), Nervous System Disorders (e.g., headache), and Gastrointestinal Disorders (e.g., gingival hyperplasia).

Serious Adverse Reactions highlighted in regulatory labeling include the risk of significant hypotension (low blood pressure) and potential for reflex tachycardia which may, in susceptible individuals, precipitate angina pectoris.

Safety-Related Restrictions

Official labeling defines specific, absolute Contraindications where Renedil must not be used due to high safety risk. These include patients with unstable angina pectoris, decompensated heart failure, or those in the immediate period following an acute myocardial infarction. Additionally, the medicine is contraindicated for use during pregnancy, and caution is advised for patients with hepatic impairment as they may experience elevated drug concentrations.

Overdose and Emergency Response

A Renedil (Felodipine) overdose is characterized by an exaggerated version of its intended effect, resulting in severe and potentially life-threatening cardiovascular manifestations. The officially documented signs of overdose include marked hypotension (severely low blood pressure) and extensive excessive peripheral vasodilatation (widening of blood vessels). These effects are sometimes accompanied by bradycardia (a slow heart rate).

The primary clinical risk documented in regulatory labels stems from this profound circulatory depression, which may lead to myocardial ischaemia (damage to heart muscle) or cerebral ischaemia. Due to the extended-release nature of the tablet, management may be prolonged.

When to Seek Immediate Medical Help

Regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose, even if an individual is not currently experiencing symptoms. Emergency services, such as the regional Poison Control Centre or a hospital emergency department, should be contacted immediately.

Urgent medical intervention is necessary if a person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose management is symptomatic and supportive, and hospital observation and continuous monitoring are required. Specific supportive measures described in regulatory protocols include patient positioning (supine with legs elevated), volume expansion, and the use of medications such as intravenous Atropine for the slow heart rate.

Therapeutic Uses of Renedil

What Renedil Treats: Main Uses and Benefits

Renedil is commonly used for the sustained control and stabilization of essential hypertension, addressing the chronic condition of elevated systemic pressure that often develops without clear symptoms. It is utilized for the management of hypertension and is relevant for addressing Chronic Stable Angina Pectoris.

The primary therapeutic benefit is that it helps ease the overall risk to the cardiovascular system, as chronic strain is a factor, and may assist with mitigating the risks of major events such as stroke or heart attack. In situations of severe hypertension, it is generally utilized as an add-on agent in combination regimens.

For patients with angina, the medication supports the heart in a manner that is relevant for easing recurrent chest discomfort, and consequently, may assist with managing the frequency of symptomatic episodes. This combined application supports overall management. Managing both high blood pressure and chronic stable angina is relevant for supporting long-term cardiovascular stability.


Quick Fact: Support for Cardiovascular Stability

Indication Category Primary Benefit Focus
Hypertension (all grades) Stabilizing systemic pressure and reducing chronic cardiovascular risk.
Stable Angina (prophylaxis) Managing the frequency and intensity of recurrent chest discomfort.

Eligibility and Restrictions for Use

Renedil (Felodipine) eligibility rules are strictly defined by regulatory authorities and limit use based on age, physiological status, and underlying health conditions.

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults with approved indications
Populations for whom use is not recommended Lactating (breastfeeding) women (due to insufficient data)
Populations for whom use is contraindicated Known hypersensitivity to felodipine or excipients

Age- and Condition-Based Eligibility

Classification Official Regulatory Status
Pediatric Patients Safety and efficacy not established; should not be used
Older Patients Clearance is reduced; low initial dose of 2.5 mg recommended
Impaired Hepatic Function Low initial dose recommended; contraindicated in severe hepatic impairment
Impaired Renal Function Dose adjustment not required
Pregnancy Contraindicated

Absolute Exclusionary Conditions

Use of Renedil is contraindicated for patients with specific acute cardiac conditions, including unstable angina pectoris, acute myocardial infarction, and decompensated heart failure, as well as haemodynamically significant cardiac valvular obstruction.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use Renedil by setting absolute contraindications for pregnancy and acute cardiac instability, which prohibit use. The profile also establishes conditional use requirements for special populations, such as mandating lower starting doses for older adults and patients with impaired hepatic function, while noting that use is not established for the pediatric population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Renedil is defined primarily by its role as a sensitive substrate for the CYP3A4 enzyme system, leading to pharmacokinetic interactions with several medicinal products and non-drug substances. No medicinal product combinations are formally classified as contraindicated in primary regulatory documents.

Category Interaction Pattern
Metabolic Inhibitors Co-administration with strong CYP3A4 inhibitors (e.g., Itraconazole, Erythromycin, Cimetidine) causes a substantial increase in Renedil's systemic exposure (AUC and C max).
Metabolic Inducers Strong CYP3A4 inducers (e.g., Rifampin, Phenytoin, Carbamazepine) cause significant decreases in plasma concentrations, which may reduce its therapeutic effect.

Interactions with Food, Substances, and Supplements

Official labeling documents note specific non-drug interactions that alter the drug's exposure or effect:

  • Grapefruit Juice: Ingestion causes approximately a two-fold increase in the plasma C max and AUC of Renedil, an interaction classified as CYP3A4 inactivation.
  • St. John's Wort: This herbal product, an CYP3A4 inducer, is documented to reduce Renedil exposure.
  • Alcohol (Ethanol): Co-ingestion may result in an additive pharmacodynamic effect in lowering blood pressure.

Additional Interaction Considerations

Renedil may act as a perpetrator drug, leading to an increase in the blood concentration of Tacrolimus. Furthermore, a population-specific note exists for patients with severe hepatic impairment, where reduced metabolic clearance can substantially prolong the drug's half-life and increase the potential for accumulation.

Mechanism of Action

Specific Blockade of L-type Calcium Channels

The core action of Renedil (Felodipine) is the highly selective inhibition of L-type voltage-gated calcium channels (Cav1.2) found primarily in the membranes of arteriolar smooth muscle cells. By binding to these channels, the drug restricts the necessary influx of extracellular calcium ions (Ca^2+), which are essential cofactors for muscle contraction. This action interrupts the excitation-contraction coupling pathway, leading to muscle fiber relaxation and immediate vasodilation.


Reduction of Peripheral Vascular Resistance

The widespread relaxation of the body's arterioles results in a significant decrease in Peripheral Vascular Resistance (PVR). This systemic vasodilation reduces the mechanical load imposed on the cardiovascular system, thereby resulting in a sustained functional decrease in systemic arterial pressure. This continuous mechanism of reducing vascular tone is maintained by the continuous channel inhibition enabled by the drug's specialized extended-release formulation.

Dosage and Administration Information

Renedil: Official Administration Guidelines

This information details the instructions for taking Renedil (felodipine extended-release tablets).


Administration Scope

Classification Rule
Route of Administration Oral (Swallow whole)
Frequency Pattern Once daily
Dosing Schedule (Adult) Typically initiated with a low dose (e.g., 2.5 mg or 5 mg) and adjusted by a healthcare provider. The usual adult dose ranges from 2.5 mg to 10 mg once daily.

Procedural Instructions

  1. Preparation and Ingestion: The extended-release tablet must be swallowed whole with a glass of water. Do not cut, crush, chew, or suck on the tablet, as this can interfere with the extended-release mechanism.
  2. Timing: Take the tablet once daily, preferably at the same time each day (e.g., in the morning) to maintain consistent drug levels in the body.
  3. Meal Considerations: Renedil may be taken with or without food. However, it should not be taken with meals that are rich in carbohydrate or fat (such as bacon, hash browns, or sugared cereals), as this may increase the amount of medicine absorbed.
  4. Avoidances: Patients must avoid consuming grapefruit and grapefruit juice while taking this medication, as it can significantly increase the drug concentration in the body.

Missed Dose Rules

  • If a dose is missed and remembered within 12 hours of the usual time, the usual dose should be taken immediately.
  • If more than 12 hours have passed since the missed dose, do not take the missed dose. Simply take the next scheduled dose at the regular time. Never take a double dose to make up for a missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Renedil

Evidence for Use in Essential Hypertension

Renedil was evaluated in research exploring systemic or functional imbalance in patients diagnosed with essential hypertension. Studies included short-term and longer-term research, often involving controlled comparisons against a placebo or other established treatments. The research examined outcomes related to systemic or functional imbalance, specifically looking at changes in both systolic and diastolic blood pressure readings.

Studies monitored the patterns of change in blood pressure readings throughout the study periods. In research where Renedil was used as part of a broader treatment plan, findings contributed to the broader evidence landscape by documenting the incidence of major cardiovascular events, such as stroke. Furthermore, studies monitored the heart’s structure, documenting measurements related to Left Ventricular Hypertrophy (LVH), which is an abnormal thickening of the heart muscle.

Evidence for Use in Chronic Stable Angina Pectoris

Renedil was studied for conditions involving periods of heightened symptoms, specifically Chronic Stable Angina. Research explored short-term symptom changes, with studies focusing on outcomes related to physical discomfort. These trials monitored responses over defined time intervals to see how Renedil was studied regarding the frequency and severity of episodes.

Findings describe patterns observed in the studies related to the weekly frequency of anginal attacks and the number of times rescue medication was used. Evidence provides insight into short-term changes for symptomatic relief in this condition. However, the evidence is limited regarding long-term cardiovascular outcomes or changes in the underlying condition.

Long-Term Studies and Cardiovascular Follow-up

Research explored long-term use of Renedil, particularly in the context of treating high blood pressure. While some controlled studies monitored responses for periods up to a year, others tracked observations over longer periods, often when Renedil was used as an add-on therapy alongside other established treatments. Renedil's inclusion in long-term combination regimens provided observations that contribute to the broader evidence landscape of treating high blood pressure.

However, research limitations exist. Follow-up durations were limited for studies where Renedil was used alone. Data are still emerging for very long-term outcomes (many years) when Renedil is not part of a multi-drug regimen.

What is Still Uncertain About Renedil

While studies help show what has been observed so far, evidence highlights what is known—and what is still uncertain. Subgroup findings are uncertain for certain ethnic or racial populations, as results apply only to the specific populations studied in the research. Comparative evidence is lacking for Renedil as a single agent versus other common treatments over very long follow-up durations regarding major cardiovascular events.

Key Studies & References

  1. Felodipine - StatPearls - NCBI Bookshelf (NIH)
  2. Pharmacokinetics of felodipine in patients with impaired renal function

Frequently Asked Questions (FAQ)

Common questions about Renedil (FAQ)


Q: How long does Renedil typically stay in the body after the last dose?

Studies on Renedil (Felodipine) indicate that the elimination half-life, which is the time it takes for half of the drug to be removed from the body, is typically between 17.5 and 31.5 hours in patients with high blood pressure. The extended half-life is consistent with its formulation as a once-daily extended-release medication.


Q: Can Renedil be taken with common over-the-counter pain relievers like ibuprofen or aspirin?

Official information notes that Renedil is a sensitive substrate for the CYP3A4 enzyme, meaning its concentration in the body can be affected by other compounds. Because of the potential for pharmacokinetic interactions, its efficacy may be reduced or altered when co-administered with certain other drugs. Reviewing all concurrent products, including over-the-counter items, with a healthcare provider is generally recommended due to potential interactions.


Q: Is Renedil safe for use in patients with pre-existing kidney problems?

According to official regulatory guidance, dose adjustment is not required for patients who have impaired kidney function. Furthermore, studies indicate that Renedil typically does not affect the normal function of the kidneys (Glomerular Filtration Rate). Eligibility for use and dosing guidance for any patient is determined by a healthcare provider.


Q: Can Renedil be taken while breastfeeding?

Regulatory documents advise that treatment with Renedil is not recommended during breastfeeding. This is because felodipine, the active ingredient, has been detected in breast milk, and there is insufficient data available on its potential effects on the nursing infant.


Q: Are the side effects of Renedil generally temporary, or do some last as long as the treatment?

Some common side effects, such as headache and flushing, are noted in official labeling to be transient, meaning they may appear at the start of treatment and subside over time. However, other very common effects, most notably peripheral edema (swelling of the ankles or feet), may be dependent on the dose and age of the patient.


Q: Does Renedil affect the ability to drive or operate machinery?

Official product information states that Renedil has a minor or moderate influence on a person's ability to drive or use machines. This caution is primarily due to the drug's known common side effects, such as dizziness and fatigue, which can impair attention or reaction time.


Q: What should be done if a dose of Renedil is missed?

Official guidance describes a specific time window (e.g., within 12 hours) for taking a missed dose or skipping it entirely if the window has passed. For example, if remembered within the allowed time frame, the usual dose may be taken immediately; otherwise, the missed dose should be skipped. Never take a double dose to make up for a missed one.


Q: Can Renedil be split, crushed, or chewed if a person has trouble swallowing pills?

No. Official procedural instructions mandate that the extended-release tablet must be swallowed whole. The tablets should not be cut, crushed, chewed, or sucked, as this action will interfere with the drug's specialized formulation and its controlled delivery mechanism.


Q: Why do some people with my condition not qualify to use Renedil?

Regulatory documents define who can and cannot use Renedil by setting absolute contraindications for specific patient groups. These include patients experiencing certain acute cardiac conditions, such as unstable angina pectoris or decompensated heart failure. The medication is also strictly contraindicated for use during pregnancy.


Q: How should Renedil be properly stored (temperature, light, moisture)?

Renedil must be stored at Controlled Room Temperature, which is typically 20^circ to 25 C (68^circ to 77 F). The container must be kept tightly closed, and the product must be protected from freezing, excessive heat, moisture, and direct light to maintain its integrity.


Q: What is the correct way to dispose of unused or expired Renedil?

The preferred method for disposal is using a drug take-back program or mail-back service. If a take-back program is unavailable, the medication should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash. Regulatory guidance advises that the medication should not be released into waterways, including by flushing.


Q: Does Renedil cause changes in appetite or body weight?

The safety profile lists unusual weight gain or loss and rapid weight gain as adverse reactions reported during clinical use. Reports of loss of appetite have also been noted in less common instances. Any changes in body weight or appetite are typically reviewed by a healthcare professional.


Q: Can Renedil affect sleep patterns, causing insomnia or excessive drowsiness?

Regulatory safety profiles list both insomnia (difficulty sleeping) and somnolence (unusual drowsiness or sleepiness) as possible adverse reactions reported during clinical trials.


Q: Does Renedil cause changes in mood or energy?

The official safety profile includes reports of psychiatric effects such as depression, anxiety, irritability, and nervousness. Additionally, unusual tiredness or weakness (asthenia) is also a reported side effect associated with the medication.


Q: Is a rash a sign of a serious side effect from Renedil?

A skin rash is noted in regulatory information as a reported side effect of the medication. Official documents emphasize the need to seek immediate medical attention if a rash occurs alongside signs of a severe allergic reaction (e.g., swelling or trouble breathing).


Q: Does Renedil interact with any common medications used for high blood pressure or diabetes?

Renedil is metabolized by the CYP3A4 enzyme, which defines many of its interactions. Specific evidence indicates that co-administration with certain diabetes medications (e.g., Albiglutide) can increase the risk of low blood sugar. Reviewing all concurrent prescriptions with a healthcare professional is generally advised.


Q: Should any specific foods be avoided while taking Renedil?

Yes, official procedural instructions state that patients must avoid grapefruit and grapefruit juice as they can significantly increase the drug's concentration in the blood. Renedil may be taken with or without food, but not with meals that are rich in carbohydrate or fat.


Q: What happens if Renedil is taken in an amount higher than the dose recommended by a doctor?

Regulatory documents state that taking more than the prescribed amount requires seeking immediate medical help or contacting a Poison Control Center. Symptoms of an overdose may include feelings of warmth and severe flushing.


Q: Is there a need for blood tests or other monitoring while taking Renedil?

While routine blood tests are not generally mentioned, the official documentation states that close monitoring of blood pressure is required during dosage adjustment, particularly for patients with impaired liver function.


Q: Is there any evidence that Renedil is addictive?

Regulatory data and official drug information indicate that Renedil is a calcium channel blocker, and no habit-forming tendency has been reported for this medication.


Q: Can Renedil cause an allergic reaction, and what are the symptoms to look for?

Hypersensitivity to Renedil is an absolute contraindication for use. Symptoms of a serious allergic reaction can include swelling of the face, lips, tongue, or extremities and difficulty breathing or swallowing, requiring immediate emergency medical treatment.


Q: Does Renedil affect fertility in men or women?

Official regulatory documents and the Summary of Product Characteristics (SmPC) state that there is no data available on the effects of felodipine on patient fertility.


Q: Can Renedil interact with supplements like melatonin for sleep?

Some evidence suggests that the supplement melatonin may decrease the blood pressure-lowering effect of felodipine. This potential interaction may reduce the medicine's overall effectiveness in controlling blood pressure.


Q: How does Renedil affect kidney or liver function?

Studies indicate that Renedil typically does not affect normal kidney function. However, the drug is metabolized by the liver, and patients with severe hepatic (liver) impairment may experience substantially increased drug concentrations.


Q: Does Renedil need to be taken at the exact same time every day?

Official instruction is to take the tablet once daily. It is noted that the medication should be taken preferably at the same time each day (e.g., in the morning) to ensure consistent drug levels and maintain a steady therapeutic effect throughout the day.


Q: Is Renedil classified as a narcotic?

No. Renedil is classified as a dihydropyridine calcium channel blocker, which is an antihypertensive medication. It is not classified as a narcotic or a controlled substance by major regulatory bodies like the U.S. Drug Enforcement Administration (DEA).


Q: Is Renedil a temperature-sensitive medication?

Yes, Renedil is considered sensitive to temperature extremes. It must be stored at Controlled Room Temperature and protected from both freezing and excessive heat, as well as from moisture and direct light, to ensure product integrity.


Q: Why do some people say Renedil didn't work for them?

Regulatory documents respect the natural variation in treatment response, noting that findings are uncertain for certain patient subgroups (e.g., ethnic or racial populations) because results apply only to the specific populations studied. Individual responses to any medication can vary, and official information is based on overall population effects.


Q: Is Renedil available as a generic drug?

The active ingredient in Renedil is Felodipine, which is the generic name for the substance. Renedil is the brand name of the extended-release formulation containing Felodipine.


Q: What are the signs that Renedil is starting to work?

A reduction in blood pressure typically occurs within 2 to 5 hours of taking Renedil. The intended result is measured by monitoring blood pressure readings, which is typically a clinical process performed by a healthcare professional.

How should Renedil be stored and disposed of?

Storage Requirements

Renedil (felodipine extended-release tablets) must be stored at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with limited excursions permitted up to 30 C (86 F). The product must be kept from freezing and protected from excessive heat, moisture, and direct light. The container must be kept tightly closed to maintain product integrity.

Child Safety and Disposal

For safety, Renedil must be stored in a location that is out of the sight and reach of children.

Unused or expired Renedil should be disposed of by following official instructions. The preferred method is using a drug take-back program or mail-back service. If unavailable, the medication should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash. The medication should not be released into waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Renedil found in:

A-Z Index: